» Articles » PMID: 31249368

Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain

Overview
Journal Sci Rep
Specialty Science
Date 2019 Jun 29
PMID 31249368
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

N,N-dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic-L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT). Whether DMT is biosynthesized in the mammalian brain is unknown. We investigated brain expression of INMT transcript in rats and humans, co-expression of INMT and AADC mRNA in rat brain and periphery, and brain concentrations of DMT in rats. INMT transcripts were identified in the cerebral cortex, pineal gland, and choroid plexus of both rats and humans via in situ hybridization. Notably, INMT mRNA was colocalized with AADC transcript in rat brain tissues, in contrast to rat peripheral tissues where there existed little overlapping expression of INMT with AADC transcripts. Additionally, extracellular concentrations of DMT in the cerebral cortex of normal behaving rats, with or without the pineal gland, were similar to those of canonical monoamine neurotransmitters including serotonin. A significant increase of DMT levels in the rat visual cortex was observed following induction of experimental cardiac arrest, a finding independent of an intact pineal gland. These results show for the first time that the rat brain is capable of synthesizing and releasing DMT at concentrations comparable to known monoamine neurotransmitters and raise the possibility that this phenomenon may occur similarly in human brains.

Citing Articles

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.

Chaves C, Dos Santos R, Dursun S, Tusconi M, Carta M, Brietzke E Front Psychiatry. 2024; 15:1485337.

PMID: 39568756 PMC: 11576444. DOI: 10.3389/fpsyt.2024.1485337.


Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.

Egger K, Aicher H, Cumming P, Scheidegger M Cell Mol Life Sci. 2024; 81(1):395.

PMID: 39254764 PMC: 11387584. DOI: 10.1007/s00018-024-05353-6.


Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects.

Martial C, Carhart-Harris R, Timmermann C Neurosci Conscious. 2024; 2024(1):niae033.

PMID: 39220326 PMC: 11363954. DOI: 10.1093/nc/niae033.


Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.

Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F CNS Drugs. 2024; 38(10):771-789.

PMID: 39033264 DOI: 10.1007/s40263-024-01101-3.


Psychotomimetic compensation versus sensitization.

Brouwer A, Carhart-Harris R, Raison C Pharmacol Res Perspect. 2024; 12(4):e1217.

PMID: 38923845 PMC: 11194300. DOI: 10.1002/prp2.1217.


References
1.
Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P . Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018; 23(11):3170-3182. PMC: 6082376. DOI: 10.1016/j.celrep.2018.05.022. View

2.
Axelrod J . Enzymatic formation of psychotomimetic metabolites from normally occurring compounds. Science. 1961; 134(3475):343. DOI: 10.1126/science.134.3475.343. View

3.
Boyson S, Alexander A . Net production of cerebrospinal fluid is decreased by SCH-23390. Ann Neurol. 1990; 27(6):631-5. DOI: 10.1002/ana.410270608. View

4.
Eaton M, Gudehithlu K, Quach T, Silvia C, Hadjiconstantinou M, Neff N . Distribution of aromatic L-amino acid decarboxylase mRNA in mouse brain by in situ hybridization histology. J Comp Neurol. 1993; 337(4):640-54. DOI: 10.1002/cne.903370409. View

5.
Timmermann C, Roseman L, Williams L, Erritzoe D, Martial C, Cassol H . DMT Models the Near-Death Experience. Front Psychol. 2018; 9:1424. PMC: 6107838. DOI: 10.3389/fpsyg.2018.01424. View